Current Headlines

  1. Eisai Enters Into Collaboration Research Agreement With University Of Dundee On Targeted Protein Degradation Toward Cancer Drug Discovery

    Eisai Co.,Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced recently that it has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)1 toward drug discovery in oncology area

  2. First Time Human-On-A-Chip Predicts In Vivo Results Based On In Vitro Model

    Hesperos Inc., pioneers of the “human-on-a-chip” in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known cardiotoxic small molecules over time, to accurately describe the drug behavior and toxic effects in vivo

  3. Nosopharm And Evotec Enter Into Collaboration To Accelerate Development Of Novel Antibiotics

    Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and Evotec SE, a drug discovery and development company, recently announce their partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate

  4. Confo Therapeutics And DyNAbind Announce Drug Discovery Collaboration To Identify Novel GPCR-Modulating Compounds

    Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR)

  5. RedHill Biopharma Announces FDA Acceptance Of New Drug Application For Talicia®

    RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Talicia®(RHB-105)1 for H. pylori infection

  6. University Partners With Bukwang Pharmaceutical Company To Develop New Drug Treatment For Parkinson’s Disease

    The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease

  7. Bioinvent Receives Ind Approval For Phase I/IIa Trial Of anti-FcγRllB Antibody

    BioInvent International AB (BINV) today announces it has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with an Investigational New Drug (IND) application for a Phase I/IIa clinical trial of an immune-modulatory anti-FcγRllB antibody in combination with an anti-PD1 antibody in solid tumors

  8. Ovid Therapeutics Receives Orphan Drug Designation From The European Commission For OV101 For The Treatment Of Angelman Syndrome

    Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the European Commission (EC) has granted orphan drug designation (ODD) to OV101 (gaboxadol) for the treatment of Angelman syndrome based on the results of the Phase 2 STARS trial

  9. Abveris And Harbour Antibodies H2L2 BV Announce Technology Co-Offering Agreement For Fully Human Antibody Discovery

    Abveris, Inc., a global leader in contract research antibody discovery, and Harbour Antibodies H2L2 BV, a wholly-owned subsidiary of Harbour BioMed, recently announced a partnership to offer fully-human antibody discovery service that combines Abveris’ antibody discovery services with the Harbour H2L2 human transgenic mouse platform

  10. Puma Biotechnology Submits A Supplemental New Drug Application To U.S. FDA For Neratinib To Treat HER2-Positive Metastatic Breast Cancer

    Puma Biotechnology, Inc., a biopharmaceutical company, has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease)